References
- Anderson DC. Sex-hormone-binding globulin-review article. Clin Endocrinol 1974; 3:69–96.
- Blossey HC, Wander HE, Koebberling J, Nagel GA. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 1984; 54:1208–1215.
- Bloom HJG. Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 1971; 25:250–265.
- Cowley TH, Brownsey BG, Harper ME, Peeling WB, Griffiths K. The effect of ACTH on plasma testosterone and androstenedione concentrations in patients with prostatic carcinoma. Acta Endocrinol 1976; 81:310–320.
- Damber J-E, Bergman B, Södergård R, Tomić R. Binding capacity of testosterone-estradiol-binding globulin (TeBg), total and calculated unbound concentrations of testosterone in patients with carcinoma of the prostate treated with orchidectomy or estrogens. J Endocrinol Invest 1983; 6: 91–94.
- Denis L, Declercq G. Progestogens in prostatic cancer. Eur Urol 1978; 4: 162–166.
- Izuo M, Yoshida M, Tominaga T, Abe O, Enomoto K, Nomura Y, Kubo K, Takatani O, for the Japanese group for MPA treatment of breast cancer. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer. Cancer 1985; 56: 2576–2579.
- Johansson J-E, Lingård G. High-dose medroxyprogesterone in the treatment of advanced prostatic carcinoma. Eur Urol 1985; 11:9–10.
- Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynod JP, Husson JM, Gareau J, Fazekas AT, Sandow J, Manfette G, Girard JG, Emond J, Heule JG. New approach in the treatment of prostatic cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4:579–585.
- Mahlke M, Grill H-J, Knapstein P, Wiegand U, Pollow K. Oral high-dose medroxyprogesterone acetate (MPA) treatment: cortisol/MPA serum profiles in relation to breast cancer regression. Oncology 1985; 42:144–149.
- Meyer WJ III, Walker PA, Emory LE, Smith ER. Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate. Fertil Steril 1985; 43:102–109.
- Nolten WE, Sholiton LJ, Strivastava LS, Knowles HC Jr, Werk EE Jr. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma. J Clin Endocrinol Metab 1976; 43:1226–1233.
- Pardridge WM. Transport of protein-bound hormones in tissues in vivo. Endocr Rev 1981; 2: 103–123.
- Pavone-Macaluso M, DeVoogt HJ, Viggiano G, Barasolo E, Lardennois B, DePauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer: Urological Group. J Urol 1986; 136:624–631.
- Pizzocaro G, DiFronzo G, Piva L, Salvioni R, Ronchi E, Cappelletti V, Giongo A, Mastroberardino E, Cozzoli C, Dormia E, Minervini S, Zanollo A, Fontanella U, Giannoni R, Maggioni A, Lasio E. Adjunctive medroxyprogesterone acetate to radical nephrectomy in category MO renal cell carcinoma. Eur Urol 1983; 9:202–206.
- Sadoff L, Lusk W. The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of Cortisol T4, LH and testosterone in patients with advanced cancer. Obstet Gynecol 1974; 2:262–266.
- Sala G, Iannotta F, Faccinetti A. Endocrinological properties of medroxyprogesterone acetate. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Delia Cuna, eds. Proceedings of the International Symposium on Medroxyprogesterone Acetate. Amsterdam, Oxford, Princeton: Exerpta Medica, 1982: 125–138.
- Sciarra F, Sorcini G, DiSilverio F, Gagliardi V. Plasma testosterone and androstenedione after orchiectomy in prostatic adenocarcinoma. Clin Endocrinol 1973; 2:101–109.
- Södergård R, BäckströmT, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982; 16:801–809.
- Siegel S. Non-parametric statistics for the behavioral sciences. Tokyo: McGraw-Hill, 1956.
- VanVeelen H, Willemse PHB, Sleijfer DT, Van der Ploeg E, Sluiter WJ, Doorenbos H. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol 1985; 15:167–170.
- Wortsman J, Khan S, Rosner W. Suppression of testos-terone-estradiol binding globulin by medroxyprogesterone acetate in polycystic ovary syndrome. Obstet Gynecol 1986; 67:705–708.